DESTINY-BILIARY TRACT CANCER-01: A PHASE 3 STUDY OF TRASTUZUMAB DERUXTECAN (T-DXD) AND RILVEGOSTOMIG VERSUS STANDARD-OF-CARE GEMCITABINE, CISPLATIN, AND DURVALUMAB FOR FIRST LINE LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING BILIARY TRACT CANCER

Registry ID

D781PC00001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA CANADA INC

Start date

2026-01-16

Last update

2024-04-24

Conditions

• HER2-AMPLIFIED BILIARY TRACT CANCERS

Related clinical trials

• AN OPEN-LABEL RANDOMIZED TRIAL OF THE EFFICACY AND SAFETY OF ZANIDATAMAB WITH STANDARD-OF-CARE THERAPY AGAINST STANDARD-OF-CARE THERAPY ALONE FOR ADVANCED HER2-POSITIVE BILIARY TRACT CANCER
• A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, GLOBAL STUDY OF RILVEGOSTOMIG IN COMBINATION WITH CHEMOTHERAPY AS ADJUVANT TREATMENT AFTER RESECTION OF BILIARY TRACT CANCER WITH CURATIVE INTENT (ARTEMIDE-BILIARY01)
• A PHASE 2B, OPEN-LABEL, SINGLE-ARM STUDY OF ZW25 MONOTHERAPY IN SUBJECTS WITH ADVANCED OR METASTATIC HER2-AMPLIFIED BILIARY TRACT CANCERS

View on source registry